Impact of Disclosing Coronary Artery Disease Polygenic Risk Score on Cardiovascular Health

Summary

The goal of this clinical trial is to evaluate whether disclosure of a non-high polygenic risk score for coronary artery disease (CAD PRS) is non-inferior to standard of care in maintaining cardiovascular health over one year among adults aged 40-75 years without cardiovascular disease and not on statins.

Eligibility

Inclusion Criteria:

* Current age 40-75 years
* Established primary care at Mass General Brigham with at least one visit in the last 2 years

Exclusion Criteria:

* High CAD PRS
* Known cardiovascular disease, defined by a diagnosis of coronary artery disease, peripheral artery disease, or cerebrovascular disease
* Currently taking LDL cholesterol- lowering or anti-inflammatory medications, including statins or colchicine
* Liver disease (cirrhosis, active hepatitis, ALT \> 3x ULN, total bilirubin \> 2x ULN and not Gilbert's Syndrome)
* Contraindication to taking colchicine or rosuvastatin (allergy, liver or kidney disease)
* Pregnancy, breastfeeding, or planning to become pregnant during the study period
* Inability to provide informed consent
* Estimated glomerular filtration rate (eGFR) \<60 mL/min/1.73 m²
* BMI ≥ 40 kg/m²
* Inability to hold breath for 10 seconds

Conditions2

Locations1 site

Browse More Trials